



**3R MATRIX**

|                      |            |           |            |
|----------------------|------------|-----------|------------|
|                      | +          | =         | -          |
| Right Sector (RS)    | ✓          | ■         | ■          |
| Right Quality (RQ)   | ✓          | ■         | ■          |
| Right Valuation (RV) | ■          | ✓         | ■          |
|                      | + Positive | = Neutral | - Negative |

**What has changed in 3R MATRIX**

|    |     |   |     |
|----|-----|---|-----|
|    | Old |   | New |
| RS | ■   | ↔ | ■   |
| RQ | ■   | ↔ | ■   |
| RV | ■   | ↔ | ■   |

**ESG Disclosure Score** NEW

**ESG RISK RATING** **38.12**  
Updated Oct 08, 2021

**High Risk**

|      |       |       |       |        |
|------|-------|-------|-------|--------|
| NEGL | LOW   | MED   | HIGH  | SEVERE |
| 0-10 | 10-20 | 20-30 | 30-40 | 40+    |

Source: Morningstar

**Company details**

|                               |                   |
|-------------------------------|-------------------|
| Market cap:                   | Rs. 49,790 cr     |
| 52-week high/low:             | Rs. 3,248 / 2,311 |
| NSE volume:<br>(No of shares) | 3.4 lakh          |
| BSE code:                     | 500420            |
| NSE code:                     | TORNTPHARM        |
| Free float:<br>(No of shares) | 4.9 cr            |

**Shareholding (%)**

|           |      |
|-----------|------|
| Promoters | 71.3 |
| FII       | 11.6 |
| DII       | 8.4  |
| Others    | 8.8  |

**Price chart**



**Price performance**

| (%)                | 1m   | 3m    | 6m   | 12m   |
|--------------------|------|-------|------|-------|
| Absolute           | -5.1 | -4.4  | 17.2 | 10.8  |
| Relative to Sensex | -7.3 | -20.5 | -9.6 | -42.0 |

Sharekhan Research, Bloomberg

**Torrent Pharmaceuticals Ltd**  
**Steady Q2; Growth prospects intact**

| Pharmaceuticals |             | Sharekhan code: TORNTPHARM |                           |
|-----------------|-------------|----------------------------|---------------------------|
| Reco/View       | Reco: Buy ↔ | CMP: Rs. 2,942             | Price Target: Rs. 3,400 ↔ |
|                 | ↑ Upgrade   | ↔ Maintain                 | ↓ Downgrade               |

**Summary**

- Torrent Pharmaceuticals Limited (Torrent) reported steady growth for Q2FY2022, though PAT missed estimates due to higher tax rate.
- The company derives ~60% of its sales collectively from Indian and Brazilian markets and management sees these two geographies as key growth drivers.
- Performance of the US business could be under pressure impacted by price erosion and absence of new launches.
- Given the strong growth outlook across Indian and Brazilian business, we retain our Buy recommendation on the stock with an unchanged PT of Rs. 3,400.

**Torrent Pharmaceuticals Limited (Torrent) reported steady growth for Q2FY2022, though PAT missed estimates due to higher tax rate. Revenue for the quarter at Rs. 2,137 crore increased by 5.9% y-o-y, backed by 13% and 21% growth in India and Brazil revenue, while US sales declined by 13%, impacted by price erosion and absence of new launches. Operating profit margin (OPM) at 30.9% dipped by 60 bps y-o-y and slightly missed estimates. Due to a high tax rate, PAT at Rs. 316 crore was up by meagre 1.9% y-o-y and missed estimates of Rs. 362 crore. Going ahead, India and Brazil business could be key growth drivers for the company, while US performance is expected to be under pressure due to higher competitive pressures.**

**Key positives**

- India business revenue grew by 13% y-o-y, led by outperformance across therapy areas.
- Brazil revenue has staged strong 21% y-o-y growth, backed by growth in large brands and new launches.
- Till Q2FY2022, Torrent has repaid debt of Rs. 490 crore.

**Key negatives**

- Delay in resolution of OAI/WL at Intrad, Dahej plants.
- Pricing pressures in the US business

**Management Commentary**

- Torrent has outpaced IPM growth in Q2 and aims to continue the outperformance backed by strong performance across therapy areas.
- The US business is witnessing heightened competitive intensity leading to double-digit price erosion, thus pressurising US sales.
- Gross margin in Q2FY2022 reflect the impact of few one-time costs, which are non-recurring in nature, thus pointing towards likely improvement in gross margin, going ahead.

**Revision in estimates – Q2FY2022 was a steady quarter for Torrent and, given sustained pricing pressures in the US markets, we have fine tuned our estimates for FY2022E and FY2023E.**

**Our Call**

**Valuation – Retain Buy with unchanged PT of Rs. 3,400:** Torrent expects a strong outlook for India business, backed by expanding reach and market share gains and likely traction in new trade generics division. Expected healthy growth in the existing portfolio, likely outperformance to the industry, and new product launches would drive Brazilian sales growth. At the CMP, the stock is trading at 37x/29x its FY2022E/FY2023E EPS. We retain our Buy recommendation on the stock with an unchanged PT of Rs. 3,400.

**Key Risks**

Delays in resolution of USFDA issues at its plants.

**Valuation (Consolidated)**

| Particulars         | Rs cr  |        |         |         |         |
|---------------------|--------|--------|---------|---------|---------|
|                     | FY2020 | FY2021 | FY2022E | FY2023E | FY2024E |
| Net sales           | 7781.0 | 8005.0 | 8722.4  | 10014.5 | 10804.5 |
| Operating Profit    | 2012.0 | 2485.0 | 2695.2  | 3204.6  | 3511.5  |
| OPM (%)             | 25.9   | 31.0   | 30.9    | 32.0    | 32.5    |
| Adjusted net profit | 1026.0 | 1252.0 | 1352.9  | 1727.1  | 1947.3  |
| EPS (Rs.)           | 60.4   | 73.6   | 79.6    | 101.6   | 114.5   |
| PER (x)             | 48.7   | 39.9   | 37.0    | 29.0    | 25.7    |
| EV/Ebitda (x)       | 27.6   | 22.0   | 19.6    | 16.1    | 14.1    |
| P/BV (x)            | 10.4   | 8.6    | 7.3     | 6.0     | 5.0     |
| ROCE (%)            | 14.8   | 17.1   | 18.2    | 20.7    | 20.5    |
| RONW (%)            | 21.5   | 23.5   | 21.3    | 22.7    | 21.3    |

Source: Company; Sharekhan estimates

**Steady quarter; Higher tax leads to PAT miss:** Torrent reported a steady performance for the quarter, though PAT missed estimates due to a higher tax rate as the company reported excess tax on account of short provision for earlier periods. Revenue for the quarter at Rs. 2,137 crore was up 5.9% y-o-y and in line with estimates. Topline growth can be attributed to 13% growth in India sales as the company outperformed IPM growth across therapy areas. US sales were lower by 13% y-o-y due to price erosion in the base business and lack of new approvals pending re-inspection of facilities, while Brazil sales grew by 21% y-o-y due to momentum in large brands and two new product launches. OPM at 30.9% dipped by 60 bps y-o-y and slightly missed estimates, as gross margins contracted by 30 bps y-o-y. EBITDA at Rs. 660 crore increased by 3.9% y-o-y, however it is slightly below estimates. Tax rate for the quarter stood higher at 33.1% as compared to 19.3% in Q2FY2021 due to shortage of provisioning in earlier period. Consequently, PAT stood at Rs. 316 crore, up 1.9% y-o-y, but missed estimates of Rs. 362 crore.

### Q2FY2022 Concall Highlights

- ♦ **India business on a strong footing:** Torrent's India business largely comprises the domestic formulations business, which has staged healthy growth of 13% y-o-y to Rs.1,087 crore in Q2FY2022. Adjusting for delayed dispatches in Q2FY2021, growth stood at 16%. Growth can be attributed to strong performance of top brands and new launches as the company outpaced IPM growth. Going ahead, a slew of growth triggers is expected to drive performance of India business. Torrent has launched its trade generic division in India in the previous quarter and has since then received good response with revenue accounting for 1.5% to 2% of total revenue. This would largely comprise acute therapy products and some of the prescription brands would also be shifted to the trade generics division. Torrent is eyeing 4-5% share of the India business, from the trade generics segment, which is substantial. In addition, strong traction is expected to sustain in the branded generics business, which would also add to revenue growth. The current field force productivity stands at Rs. 9.9 lakh for the quarter, which is strong. Overall, focus on growing the trade generics business, strong growth in branded generics, and improvement in field-force productivity could be key growth drivers for India business.
- ♦ **US Business witnesses heightened competition:** Torrent's US business has been under severe stress as two of its key plants catering to the US markets – Dahej and Indrad – have been under the scrutiny of the USFDA. This affected the base business as well as new product launches, with the new launch momentum hit severely. US sales for the quarter stood at Rs. 284 crore, which is a decline of 13% y-o-y. Constant currency sales for the quarter stood at \$35 million. Going ahead, management sees US business to be under stress in the near term to medium term as competitive intensity is on the higher side, leading to double-digit price erosion, which could sustain ahead as well. Moreover, as the company's plants are under USFDA scrutiny, the new product launch momentum has been slow and would improve only with regulatory approvals flowing in. Torrent has a strong product pipeline comprising 53 ANDAs pending approval and seven tentative approvals. Collectively, based on the above, performance in US markets could be under stress and USFDA clearances for both Dahej and Indrad plants is awaited and is critical for US revenue growth.
- ♦ **Brazil markets:** Revenue from Brazil rose impressively by 21% y-o-y to Rs. 156 crore, making it the fastest growing region in the quarter. Strong growth can be attributed to momentum in large brands and two sizeable new product launches. Torrent has outperformed the industry's growth in Brazil markets and expects to continue outperforming the industry. Further, the company plans to launch three molecules in Brazil markets by FY2022, which could add to growth.
- ♦ **Europe (Germany) sales** declined by 4% y-o-y to Rs. 251 crore. Performance was impacted by COVID-induced supply delays and inventory normalisation led by customer consolidation.
- ♦ **Gross margin:** Gross margin for Q2FY2022 has declined marginally on a y-o-y basis. Margin performance for the quarter has been influenced by adverse mix in India operations (higher share of the acute segment), higher inventory provisioning for generic markets (impact 0.5%), and pricing pressures in the US (impact 0.3%). Going ahead, management expects the mix in India operations to correct and shift in favour of chronics and the inventory provisioning was a one-time hit. Hence, gross margins are expected to be at 72-73% levels in the coming quarters.

- ◆ **ANDA approvals (US markets):** As of September 2021, the company has 53 ANDAs pending approvals with the USFDA and the company receiving seven tentative approvals.
- ◆ **Debt repayment:** Till Q2FY2022, the company has repaid around Rs. 490 crore and expects net debt to be ~Rs. 3,500 crore by the end of FY2022.

**Results (Consolidated)**

| Particulars             | Rs cr        |              |            |              |             |
|-------------------------|--------------|--------------|------------|--------------|-------------|
|                         | Q2FY2022     | Q2FY2021     | Y-o-Y %    | Q1FY2022     | Q-o-Q %     |
| Total Sales             | 2,137.0      | 2,017.0      | 5.9        | 2,134.0      | 0.1         |
| Expenditure             | 1,477.0      | 1,382.0      | 6.9        | 1,457.0      | 1.4         |
| <b>Operating profit</b> | <b>660.0</b> | <b>635.0</b> | <b>3.9</b> | <b>677.0</b> | <b>-2.5</b> |
| Other income            | 51.0         | 6.0          | 750.0      | 40.0         | 27.5        |
| EBITDA                  | 711.0        | 641.0        | 10.9       | 717.0        | -0.8        |
| Interest                | 71.0         | 92.0         | -22.8      | 68.0         | 4.4         |
| Depreciation            | 168.0        | 165.0        | 1.8        | 165.0        | 1.8         |
| PBT                     | 472.0        | 384.0        | 22.9       | 484.0        | -2.5        |
| Taxes                   | 156.0        | 74.0         | 110.8      | 154.0        | 1.3         |
| PAT                     | 316.0        | 310.0        | 1.9        | 330.0        | -4.2        |
| EPS (Rs.)               | 18.6         | 18.2         | 1.9        | 19.4         | -4.2        |
| <b>Margins</b>          |              |              | <b>BPS</b> |              | <b>BPS</b>  |
| OPM %                   | 30.9         | 31.5         | -60        | 31.7         | -84         |
| PATM %                  | 14.8         | 15.4         | -58        | 15.5         | -68         |
| Tax %                   | 33.1         | 19.3         | 1,378      | 31.8         | 123         |

Source: Company; Sharekhan Research

## Outlook and Valuation

■ **Sector View – Growth momentum to improve:** Indian pharmaceutical companies are better placed to harness opportunities and report healthy growth going ahead. Indian companies are among the most competitive ones globally and hold a sizeable market share in most developed as well as other markets. Moreover, other factors such as easing of pricing pressures (especially in the US generics market), rise in product approvals, plant resolutions by the USFDA, and strong growth prospects in domestic markets and emerging opportunities in the API space would be key growth drivers. This would be complemented by strong capabilities developed by Indian companies (leading to a shift towards complex molecules and biosimilars) and commissioning of expanded capacities by select players over the medium term. Collectively, this indicates a strong growth potential going ahead for pharmaceutical companies.

■ **Company outlook – Indian, Brazilian businesses to stage strong growth:** Torrent is a leading pharmaceutical company present in emerging as well as developed markets. The company has a higher exposure to chronic therapies. Moreover, the company derives a substantial portion of its sales from India, followed by the US, Germany, and Brazil, which collectively form the core markets. The company has been outperforming in the Indian as well as Brazilian markets and management expects to sustain the traction going ahead as well and sees these geographies as key growth drivers. Moreover, the German business is expected to gain traction and stage strong growth ahead, backed by growth in the base business and new product launches. The US business of the company has been under pressure as two of its plants, which cater to US markets – Dahej and Indrad – are under the USFDA's scanner with OAI/WL classification. However, the Levittown plant has commenced operations and the company expects to launch a new product in the US market from the plant, which could help it mitigate pricing pressures. A timely and successful resolution of these USFDA observations at its two plants is critical and upon resolution could result in earnings upgrades.

### ■ Valuation – Retain Buy unchanged PT of Rs. 3,400

Torrent expects a strong outlook for the India business backed by expanding reach and market share gains while it has also set up a trade generics division to focus on acute therapy products with an objective to expand product portfolio and gain market share. Revenue share of trade generics is likely to reach 4-5% of India sales in the next one year, which is sizeable. Expected healthy growth in existing portfolio, likely outperformance to the industry, and new product launches would drive Brazilian sales growth. Management sees India and Brazil as key growth drivers while it sees European performance to improve from hereon. US sales are expected to be under stress, marred by pricing erosion, while Dahej and Indrad plants continue to be under USFDA's scrutiny. A successful resolution for both the plants is awaited. Given sustained pricing pressures in US markets, we have fine tuned our estimates for FY2022E and FY2023E. At the CMP, the stock is trading at 37x/29x its FY2022E/FY2023E EPS. Given better growth prospects across Indian and Brazilian business, we retain Buy on the stock with an unchanged PT of Rs. 3,400.

### One-year forward P/E (x) band



Source: Sharekhan Research

### Peer valuation

| Particulars    | CMP<br>(Rs /<br>Share) | O/S<br>Shares<br>(Cr) | MCAP<br>(Rs Cr) | P/E (x) |       |       | EV/EBIDTA (x) |       |       | RoE (%) |       |       |
|----------------|------------------------|-----------------------|-----------------|---------|-------|-------|---------------|-------|-------|---------|-------|-------|
|                |                        |                       |                 | FY21    | FY22E | FY23E | FY21          | FY22E | FY23E | FY21    | FY22E | FY23E |
| Torrent Pharma | 2942                   | 16.99                 | 49790           | 40.9    | 36.4  | 28.9  | 22.4          | 19.5  | 16.1  | 23.5    | 22.0  | 23.0  |
| Cipla          | 907.0                  | 80.6                  | 73187.0         | 30.5    | 23.8  | 19.8  | 17.5          | 14.9  | 12.4  | 13.9    | 14.6  | 16.1  |
| Lupin          | 930                    | 45.3                  | 42,215          | 34.7    | 25.3  | 18.6  | 18.1          | 10.8  | 7.9   | 8.8     | 11.0  | 13.3  |

Source: Company, Sharekhan estimates

## About company

Torrent, the flagship company of Torrent Group, was incorporated in 1972. Torrent has a strong international presence across 40 countries with operations in regulated and emerging markets such as the US, Europe, Brazil, and the Rest of the World. The company operates through its wholly owned subsidiaries spread across 12 nations with major setups in Brazil, Germany, and the US. The company is also one of the leading pharmaceutical companies present in India as a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS). The company also has a significant presence in gastro-intestinal, diabetology, anti-infectives, and pain management segments.

## Investment theme

Torrent continues to focus on a branded business mix from India and Brazil, which balances well for sustainable growth in a challenging global environment for the pharma sector. US business is also stable. Operating leverage from the acquired domestic business is likely to be visible from FY2020. Three manufacturing plants of Torrent are reeling under regulatory issues with a warning letter being issued by the USFDA. Management expects at least 12-15 months for the issues to be resolved; and till such time, approvals from these plants would be withheld. Torrent has submitted its responses to the regulator and is awaiting a revert on this. Timely and successful resolution of USFDA issues is critical from the growth perspective.

## Key Risks

- ◆ Slowdown in ANDA approvals and USFDA-related regulatory risks could hurt business prospects.
- ◆ Delay in product launches in Brazil, Germany, and US could restrict growth in these key geographies.
- ◆ Currency fluctuation poses a risk to export businesses.

## Additional Data

### Key management personnel

|                  |                     |
|------------------|---------------------|
| Mr. Sudhir Mehta | Chairman (Emeritus) |
| Mr. Samir Mehta  | Executive Chairman  |
| Mr. Sudhir Menon | CFO                 |

Source: Company Website

### Top 10 shareholders

| Sr. No. | Holder Name                           | Holding (%) |
|---------|---------------------------------------|-------------|
| 1       | Mirae Asset Global investment Company | 2.14        |
| 2       | UTI Asset Management Co Ltd           | 1.37        |
| 3       | FMR LLC                               | 1.31        |
| 4       | Blackrock Inc                         | 0.88        |
| 5       | Vanguard Group Inc                    | 0.87        |
| 6       | Pictet Funds SA                       | 0.76        |
| 7       | T Rowe Price Group Inc                | 0.72        |
| 8       | Kotak Mahindra Asset Management Co    | 0.62        |
| 9       | Norges Bank                           | 0.50        |
| 10      | ICICI Prudential Life Insurance Co    | 0.48        |

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

## Understanding the Sharekhan 3R Matrix

| Right Sector    |  |
|-----------------|--|
| Positive        | Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies   |
| Neutral         | Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies  |
| Negative        | Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability. |
| Right Quality   |  |
| Positive        | Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.   |
| Neutral         | Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable  |
| Negative        | Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet   |
| Right Valuation |  |
| Positive        | Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.                        |
| Neutral         | Trading at par to historical valuations and having limited scope of expansion in valuation multiples.  |
| Negative        | Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.   |

Source: Sharekhan Research

# Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.

# Sharekhan Research Coverage/Universe

## Automobiles

Alicon Castalloy Limited  
Apollo Tyres  
Ashok Leyland  
Amara Raja Batteries Limited  
Bajaj Auto  
Balkrishna Industries  
Bosch Limited  
Exide Industries Limited  
Gabriel India Limited  
GNA Axles Limited  
Greaves Cotton  
Hero MotoCorp  
Lumax Auto Technologies Limited  
M&M  
Maruti Suzuki  
Mayur Uniquoters  
Ramkrishna Forgings Limited  
Schaeffler India Limited  
Sundram Fasteners  
Suprajit Engineering Limited  
Tata Motors Limited  
TVS Motor

## Banks & Finance

AU Small Finance Bank  
Axis Bank  
Bajaj Finance  
Bajaj Finserv  
Bank of Baroda  
Bank of India  
Capital First  
Cholamandalam Investment and Finance Company  
City Union Bank  
Federal Bank  
Housing Development Finance Corporation  
HDFC Bank  
HDFC Life Insurance  
ICICI Bank  
ICICI Lombard General Insurance  
ICICI Prudential Life Insurance Company Ltd  
IndusInd Bank  
Kotak Mahindra Bank  
LIC Housing Finance  
L&T Finance Holding  
Max Financial Services  
Mahindra & Mahindra Financial Services  
Nippon Life India Asset Management Limited  
Punjab National Bank  
RBL Bank  
Repco Home Finance Limited  
SBI  
Union Bank of India

## Consumer goods

Asian Paints Limited  
Britannia  
Colgate Palmolive (India)  
Dabur India Limited  
Emami  
GSK Consumers  
Godrej Consumer Products  
Hindustan Unilever Limited  
Indigo Paints Ltd  
ITC  
Jyothy Laboratories Limited  
Marico  
Nestle India Limited  
Radico Khaitan Ltd  
Tata Consumer Products Ltd  
Zydus Wellness

## IT / IT services

Birlasoft Limited  
HCL Technologies  
Infosys  
Intellect Design Arena Limited  
Larsen & Toubro Infotech  
L&T Technology Services  
Mastek Limited  
Persistent Systems  
Tata Consultancy Services  
Tata Elxsi Limited  
Tech Mahindra  
Wipro

## Capital goods / Power

Amber Enterprises Limited  
Blue Star Limited  
Carborundum Universal Limited  
CESC  
Cummins India  
Dixon Technologies Limited  
Finolex Cables  
Honeywell Automation India Limited  
Kalpataru Power Transmission  
Polycab India Limited  
Power Grid Corporation of India Limited  
NTPC Limited  
KEC International  
KEI Industries  
Tata Power Company Ltd  
Thermax  
Triveni Turbine  
V-Guard Industries  
Va Tech Wabag Ltd.

## Infrastructure / Real estate

Ashoka Buildcon Limited  
JMC Projects (India) Limited  
Larsen & Toubro  
Mahindra Lifespace Developers Limited  
KNR Constructions Limited  
PNC Infratech Limited  
Sadbhav Engineering

## Oil & gas

Bharat Petroleum Corporation Limited  
Castrol India Limited  
GAIL (India) Limited  
Gujarat Gas Ltd.  
Gujarat State Petronet Limited  
Hindustan Petroleum Corporation Limited  
Indraprastha Gas Limited  
Indian Oil Corporation Ltd  
Mahanagar Gas  
Oil India  
Petronet LNG  
Reliance Industries

## Pharmaceuticals

Abbott India Limited  
Aurobindo Pharma  
Biocon  
Cipla  
Cadila Healthcare  
Divi's Labs  
Dr Reddy's Laboratories Limited  
Gland Pharma Limited  
Granules India Limited  
Ipca Laboratories Limited  
Laurus Labs Limited  
Lupin

Sanofi India  
Solara Active Pharma Sciences  
Strides Pharma Sciences  
Sun Pharmaceutical Industries  
Torrent Pharmaceuticals

## Building materials

Astral Poly Technik Limited  
APL Apollo Tubes Limited  
Dalmia Bharat Limited  
Grasim Industries  
Greenlam Industries Limited  
Greenpanel Industries Limited  
JK Lakshmi Cement Limited  
Kajaria Ceramics Limited  
Pidilite Industries Limited  
The Ramco Cements  
Shree Cement  
UltraTech Cement

## Discretionary consumption

Aditya Birla Fashion and Retail Limited  
Arvind Ltd.  
Bata India Limited  
Century Plyboards (India)  
Inox Leisure  
Indian Hotels Company Limited  
Info Edge (India)  
Jubilant FoodWorks Limited  
PVR Ltd  
Relaxo Footwear  
Titan Company  
Trent Limited  
Welspun India Limited  
Wonderla Holidays  
Zee Entertainment Enterprises Limited

## Diversified / Miscellaneous

Aarti Industries Limited  
Affle (India) Limited  
Atul Limited  
Bajaj Holdings & Investment  
Bharti Airtel  
Bharat Electronics  
Coromandel International Limited  
Coal India Limited  
Gateway Distriparks  
Insecticides (India) Limited  
JSW Steel Limited  
Mahindra Logistics Limited  
MOIL Limited  
NMDC Limited  
PI Industries  
Polyplex Corporation Limited  
Quess Corp Limited  
Ratnamani Metals and Tubes  
Steel Authority of India Ltd  
SRF Limited  
TCI Express Limited  
Transport Corporation of India Limited  
Triveni Engineering & Industries Limited  
Sudarshan Chemical Industries  
Sumitomo Chemical India Limited  
Supreme Industries  
UPL  
Vinati Organics Limited

**Peer Comparison**

| Particulars | CMP      | P/BV(x) |       | P/E(x) |       | RoA (%) |       | RoE (%) |       |
|-------------|----------|---------|-------|--------|-------|---------|-------|---------|-------|
|             | Rs/Share | FY20E   | FY21E | FY20E  | FY21E | FY20E   | FY21E | FY20E   | FY21E |
| X           | X        | X       | X     | X      | X     | X       | X     | X       | X     |
| X           | X        | X       | X     | X      | X     | X       | X     | X       | X     |
| X           | X        | X       | X     | X      | X     | X       | X     | X       | X     |
| X           | X        | X       | X     | X      | X     | X       | X     | X       | X     |

Source: Company, Sharekhan research

**Peer valuation**

| Particulars | CMP (Rs / Share) | O/S Shares (Cr) | MCAP (Rs Cr) | P/E (x) |       | EV/EBIDTA (x) |       | P/BV (x) |       | RoE (%) |       |
|-------------|------------------|-----------------|--------------|---------|-------|---------------|-------|----------|-------|---------|-------|
|             |                  |                 |              | FY20E   | FY21E | FY20E         | FY21E | FY20E    | FY21E | FY20E   | FY21E |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X                | X               | X            | X       | X     | X             | X     | X        | X     | X       | X     |

Source: Company, Sharekhan estimates

**Peer Comparison**

| Particulars | P/E (x) |       | EV/EBITDA (x) |       | P/BV (x) |       | RoE (%) |       |
|-------------|---------|-------|---------------|-------|----------|-------|---------|-------|
|             | FY20E   | FY21E | FY20E         | FY21E | FY20E    | FY21E | FY20E   | FY21E |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |
| X           | X       | X     | X             | X     | X        | X     | X       | X     |

Source: Sharekhan Research

**Peer Comparison**

| Particulars | P/E (x) |       |       | EV/EBIDTA (x) |       |       | RoCE (%) |       |       |
|-------------|---------|-------|-------|---------------|-------|-------|----------|-------|-------|
|             | FY19    | FY20E | FY21E | FY19          | FY20E | FY21E | FY19     | FY20E | FY21E |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |
| X           | X       | X     | X     | X             | X     | X     | X        | X     | X     |

Source: Company, Sharekhan estimates

**Peer Comparison**

| Particulars | P/E (x) |         | EV/EBIDTA (x) |         | RoE (%) |         | D: E    |         |
|-------------|---------|---------|---------------|---------|---------|---------|---------|---------|
|             | FY2020E | FY2021E | FY2020E       | FY2021E | FY2020E | FY2021E | FY2020E | FY2021E |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |
| X           | X       | X       | X             | X       | X       | X       | X       | X       |

Source: Sharekhan Research

# Investor's Eye

October XX, 2021

---

## Index

### Stock Update

XXXX

XXXX

### Viewpoint

XXXX

XXXX

### Sector Update

XXXX

XXXX

Visit us at [www.sharekhan.com](http://www.sharekhan.com)

# Sharekhan

by BNP PARIBAS

For Private Circulation only